Mechanisms of Sensitivity and Resistance to Mirvetuximab Soravtansine: Ovarian Cancer and Mesothelioma

Grant

Date/time Interval

  • December 18, 2018 - December 17, 2020
  • Total Award Amount

  • 74250.00
  • Direct Costs

  • 59400.00
  • Sponsor Award Id

  • Contributor

  • Birrer M.D., Ph.D. M.D., Ph.D., Michael J.   Principal Investigator